Revvity, Inc. (RVTY) EV/Sales Ratio: 4.63x
Is Revvity, Inc.’s EV/Sales ratio high or low?
Revvity, Inc.'s EV/Sales ratio of 4.63x is 17% below its 5-year average of 5.57x, near the low end of its 5-year range (3.92x–6.90x).
As of Wednesday, June 17, 2026. 2.88% below its 12-month average of 4.77x.
RVTY EV/Sales Ratio Chart
RVTY Average EV/Sales Ratio Chart
RVTY Current vs Average EV/Sales Ratio Chart
RVTY EV/Sales Ratio Metrics
EV/SALES RATIO
4.63x
EV/SALES RATIO AVG TTM
4.77x
EV/SALES RATIO AVG 3Y
5.56x
EV/SALES RATIO AVG 5Y
5.57x
EV/SALES RATIO AVG 10Y
4.80x
EV/SALES RATIO AVG 15Y
3.97x
EV/SALES RATIO AVG 20Y
3.39x
CURRENT VS TTM AVG
-2.88%
CURRENT VS 3Y AVG
-16.66%
CURRENT VS 5Y AVG
-16.88%
CURRENT VS 10Y AVG
-3.51%
CURRENT VS 15Y AVG
+16.50%
CURRENT VS 20Y AVG
+36.67%
RVTY Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 4.63x | 4.77x | 5.56x | 5.57x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Baxter International Inc. (BAX)vs › | $10.19B | 1.61x | 1.71x | 2.16x | 2.63x |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 2.80x | 2.72x | 4.05x | 5.87x |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 3.55x | 4.14x | 5.15x | 5.80x |
| Solventum Corporation (SOLV)vs › | $12.91B | 2.13x | 2.19x | 2.26x | 2.26x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | 2.93x | 2.80x | 3.02x | 3.78x |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 4.74x | 6.02x | 5.55x | 5.39x |
| Tempus AI, Inc. (TEM)vs › | $8.51B | 6.99x | 11.36x | 12.16x | 12.16x |
| DaVita Inc. (DVA)vs › | $13.46B | 1.94x | 1.81x | 1.84x | 1.85x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Revvity, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Revvity, Inc. (RVTY)?
- The EV/Sales ratio for RVTY stock is 4.63x.
- Is Revvity, Inc.'s EV/Sales ratio high or low?
- Revvity, Inc.'s EV/Sales ratio of 4.63x is 17% below its 5-year average of 5.57x, near the low end of its 5-year range (3.92x–6.90x).
- What is the TTM average EV/Sales ratio for Revvity, Inc. (RVTY)?
- The TTM average EV/Sales ratio for RVTY stock is 4.77x.
- What is the 3Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
- The 3Y average EV/Sales ratio for RVTY stock is 5.56x.
- What is the 5Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
- The 5Y average EV/Sales ratio for RVTY stock is 5.57x.
- What is the 10Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
- The 10Y average EV/Sales ratio for RVTY stock is 4.80x.
- What is the 15Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
- The 15Y average EV/Sales ratio for RVTY stock is 3.97x.
- What is the 20Y average EV/Sales ratio for Revvity, Inc. (RVTY)?
- The 20Y average EV/Sales ratio for RVTY stock is 3.39x.
Revvity, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-17 | 4.63x |
| 2026-06-16 | 4.76x |
| 2026-06-15 | 4.73x |
| 2026-06-12 | 4.70x |
| 2026-06-11 | 4.77x |
| 2026-06-10 | 4.76x |
| 2026-06-09 | 4.87x |
| 2026-06-08 | 4.72x |
| 2026-06-05 | 4.65x |
| 2026-06-04 | 4.80x |
| 2026-06-03 | 4.75x |
| 2026-06-02 | 4.73x |
| 2026-06-01 | 4.73x |
| 2026-05-29 | 4.89x |
| 2026-05-28 | 4.76x |
| 2026-05-27 | 4.59x |
| 2026-05-26 | 4.59x |
| 2026-05-22 | 4.59x |
| 2026-05-21 | 4.53x |
| 2026-05-20 | 4.51x |
| 2026-05-19 | 4.55x |
| 2026-05-18 | 4.54x |
| 2026-05-15 | 4.48x |
| 2026-05-14 | 4.57x |
| 2026-05-13 | 4.52x |
| 2026-05-12 | 4.69x |
| 2026-05-11 | 4.83x |
| 2026-05-08 | 4.91x |
| 2026-05-07 | 4.83x |
| 2026-05-06 | 4.84x |
| 2026-05-05 | 4.57x |
| 2026-05-04 | 4.34x |
| 2026-05-01 | 4.35x |
| 2026-04-30 | 4.34x |
| 2026-04-29 | 4.17x |
| 2026-04-28 | 4.29x |
| 2026-04-27 | 4.35x |
| 2026-04-24 | 4.35x |
| 2026-04-23 | 4.36x |
| 2026-04-22 | 4.65x |
| 2026-04-21 | 4.65x |
| 2026-04-20 | 4.60x |
| 2026-04-17 | 4.63x |
| 2026-04-16 | 4.46x |
| 2026-04-15 | 4.59x |
| 2026-04-14 | 4.62x |
| 2026-04-13 | 4.58x |
| 2026-04-10 | 4.47x |
| 2026-04-09 | 4.49x |
| 2026-04-08 | 4.49x |
| 2026-04-07 | 4.39x |
| 2026-04-06 | 4.41x |
| 2026-04-02 | 4.43x |
| 2026-04-01 | 4.39x |
| 2026-03-31 | 4.38x |
| 2026-03-30 | 4.27x |
| 2026-03-27 | 4.23x |
| 2026-03-26 | 4.36x |
| 2026-03-25 | 4.39x |
| 2026-03-24 | 4.38x |
| 2026-03-23 | 4.36x |
| 2026-03-20 | 4.32x |
| 2026-03-19 | 4.31x |
| 2026-03-18 | 4.28x |
| 2026-03-17 | 4.37x |
| 2026-03-16 | 4.34x |
| 2026-03-13 | 4.30x |
| 2026-03-12 | 4.27x |
| 2026-03-11 | 4.46x |
| 2026-03-10 | 4.49x |
| 2026-03-09 | 4.56x |
| 2026-03-06 | 4.53x |
| 2026-03-05 | 4.74x |
| 2026-03-04 | 4.81x |
| 2026-03-03 | 4.71x |
| 2026-03-02 | 4.70x |
| 2026-02-27 | 4.81x |
| 2026-02-26 | 4.83x |
| 2026-02-25 | 4.78x |
| 2026-02-24 | 4.78x |
| 2026-02-23 | 4.93x |
| 2026-02-20 | 5.07x |
| 2026-02-19 | 5.05x |
| 2026-02-18 | 4.96x |
| 2026-02-17 | 4.84x |
| 2026-02-13 | 4.89x |
| 2026-02-12 | 4.87x |
| 2026-02-11 | 5.10x |
| 2026-02-10 | 5.25x |
| 2026-02-09 | 5.17x |
| 2026-02-06 | 5.12x |
| 2026-02-05 | 5.03x |
| 2026-02-04 | 5.21x |
| 2026-02-03 | 5.10x |
| 2026-02-02 | 5.35x |
| 2026-01-30 | 5.42x |
| 2026-01-29 | 5.41x |
| 2026-01-28 | 5.52x |
| 2026-01-27 | 5.66x |
| 2026-01-26 | 5.67x |
| 2026-01-23 | 5.75x |
| 2026-01-22 | 5.79x |
| 2026-01-21 | 5.74x |
| 2026-01-20 | 5.55x |
| 2026-01-16 | 5.57x |
| 2026-01-15 | 5.69x |
| 2026-01-14 | 5.53x |
| 2026-01-13 | 5.48x |
| 2026-01-12 | 5.21x |
| 2026-01-09 | 5.24x |
| 2026-01-08 | 5.12x |
| 2026-01-07 | 5.18x |
| 2026-01-06 | 5.26x |
| 2026-01-05 | 5.14x |
| 2026-01-02 | 4.97x |
| 2025-12-31 | 4.92x |
| 2025-12-30 | 4.94x |
| 2025-12-29 | 4.93x |
| 2025-12-26 | 4.92x |
| 2025-12-24 | 4.92x |
| 2025-12-23 | 4.95x |
| 2025-12-22 | 4.96x |
| 2025-12-19 | 4.89x |
| 2025-12-18 | 4.89x |
| 2025-12-17 | 4.92x |
| 2025-12-16 | 4.90x |
| 2025-12-15 | 5.01x |
| 2025-12-12 | 5.07x |
| 2025-12-11 | 5.22x |
| 2025-12-10 | 5.20x |
| 2025-12-09 | 5.00x |
| 2025-12-08 | 5.04x |
| 2025-12-05 | 5.08x |
| 2025-12-04 | 5.16x |
| 2025-12-03 | 5.19x |
| 2025-12-02 | 5.17x |
| 2025-12-01 | 5.15x |
| 2025-11-28 | 5.24x |
| 2025-11-26 | 5.25x |
| 2025-11-25 | 5.28x |
| 2025-11-24 | 5.08x |
| 2025-11-21 | 4.98x |
| 2025-11-20 | 4.80x |
| 2025-11-19 | 4.73x |
| 2025-11-18 | 4.76x |
| 2025-11-17 | 4.68x |
| 2025-11-14 | 4.75x |
| 2025-11-13 | 4.78x |
| 2025-11-12 | 4.81x |
| 2025-11-11 | 4.81x |
| 2025-11-10 | 4.73x |
| 2025-11-07 | 4.67x |
| 2025-11-06 | 4.61x |
| 2025-11-05 | 4.74x |
| 2025-11-04 | 4.70x |
| 2025-11-03 | 4.76x |
| 2025-10-31 | 4.78x |
| 2025-10-30 | 4.67x |
| 2025-10-29 | 4.85x |
| 2025-10-28 | 4.90x |
| 2025-10-27 | 4.93x |
| 2025-10-24 | 5.01x |
| 2025-10-23 | 4.95x |
| 2025-10-22 | 4.87x |
| 2025-10-21 | 4.92x |
| 2025-10-20 | 4.85x |
| 2025-10-17 | 4.78x |
| 2025-10-16 | 4.80x |
| 2025-10-15 | 4.72x |
| 2025-10-14 | 4.68x |
| 2025-10-13 | 4.67x |
| 2025-10-10 | 4.56x |
| 2025-10-09 | 4.70x |
| 2025-10-08 | 4.71x |
| 2025-10-07 | 4.68x |
| 2025-10-06 | 4.77x |
| 2025-10-03 | 4.80x |
| 2025-10-02 | 4.69x |
| 2025-10-01 | 4.71x |
| 2025-09-30 | 4.53x |
| 2025-09-29 | 4.39x |
| 2025-09-26 | 4.38x |
| 2025-09-25 | 4.34x |
| 2025-09-24 | 4.40x |
| 2025-09-23 | 4.45x |
| 2025-09-22 | 4.47x |
| 2025-09-19 | 4.49x |
| 2025-09-18 | 4.54x |
| 2025-09-17 | 4.44x |
| 2025-09-16 | 4.43x |
| 2025-09-15 | 4.38x |
| 2025-09-12 | 4.33x |
| 2025-09-11 | 4.45x |
| 2025-09-10 | 4.32x |
| 2025-09-09 | 4.42x |
| 2025-09-08 | 4.48x |
| 2025-09-05 | 4.49x |
| 2025-09-04 | 4.45x |
| 2025-09-03 | 4.35x |
| 2025-09-02 | 4.54x |
| 2025-08-29 | 4.64x |
| 2025-08-28 | 4.60x |
| 2025-08-27 | 4.57x |
| 2025-08-26 | 4.68x |
| 2025-08-25 | 4.72x |
| 2025-08-22 | 4.81x |
| 2025-08-21 | 4.62x |
| 2025-08-20 | 4.70x |
| 2025-08-19 | 4.69x |
| 2025-08-18 | 4.62x |
| 2025-08-15 | 4.66x |
| 2025-08-14 | 4.61x |
| 2025-08-13 | 4.67x |
| 2025-08-12 | 4.55x |
| 2025-08-11 | 4.46x |
| 2025-08-08 | 4.50x |
| 2025-08-07 | 4.48x |
| 2025-08-06 | 4.46x |
| 2025-08-05 | 4.58x |
| 2025-08-04 | 4.62x |
| 2025-08-01 | 4.62x |
| 2025-07-31 | 4.61x |
| 2025-07-30 | 4.73x |
| 2025-07-29 | 4.89x |
| 2025-07-28 | 4.92x |
| 2025-07-25 | 5.29x |
| 2025-07-24 | 5.22x |
| 2025-07-23 | 5.11x |
| 2025-07-22 | 4.96x |
| 2025-07-21 | 4.73x |
| 2025-07-18 | 4.84x |
| 2025-07-17 | 4.94x |
| 2025-07-16 | 4.91x |
| 2025-07-15 | 4.95x |
| 2025-07-14 | 5.06x |
| 2025-07-11 | 5.20x |
| 2025-07-10 | 5.23x |
| 2025-07-09 | 5.14x |
| 2025-07-08 | 5.16x |
| 2025-07-07 | 5.07x |
| 2025-07-03 | 5.19x |
| 2025-07-02 | 5.17x |
| 2025-07-01 | 5.09x |
| 2025-06-30 | 4.99x |
| 2025-06-27 | 5.04x |
| 2025-06-26 | 5.08x |
| 2025-06-25 | 5.03x |
| 2025-06-24 | 4.97x |
| 2025-06-23 | 4.91x |
| 2025-06-20 | 4.91x |
| 2025-06-18 | 4.89x |
| 2025-06-17 | 4.88x |
| 2025-06-16 | 4.97x |
| 2025-06-13 | 4.85x |
| 2025-06-12 | 4.94x |
| 2025-06-11 | 4.96x |
| 2025-06-10 | 4.97x |
| 2025-06-09 | 4.82x |
| 2025-06-06 | 4.78x |
| 2025-06-05 | 4.72x |
Showing the most recent 260 of 4,969 data points. The chart above shows the full history.
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh